Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Public-Health-Emergency-of-International-Concern"

10 News Found

Roche responds to WHO’s declaration of health emergency due to mpox outbreak
Healthcare | August 23, 2024

Roche responds to WHO’s declaration of health emergency due to mpox outbreak

Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants


Health Minister Nadda reviews Monkeypox situation and preparedness
Policy | August 19, 2024

Health Minister Nadda reviews Monkeypox situation and preparedness

Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management


BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development
Diagnostic Center | September 20, 2023

BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development

The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases


NIH and Exothera partner to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US
News | August 24, 2023

NIH and Exothera partner to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials


Seven manufacturers sign sublicence agreements with the MPP to produce generic versions of Shionogi's COVID-19 oral antiviral ensitrelvir
News | June 27, 2023

Seven manufacturers sign sublicence agreements with the MPP to produce generic versions of Shionogi's COVID-19 oral antiviral ensitrelvir

Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.


Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment
News | October 04, 2022

Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment

Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.


Health Secretary addresses workshop on 'Roadmap to Strengthen Public Health Preparedness and Response Capabilities of Points of Entry (PoEs) in India'
Policy | September 08, 2022

Health Secretary addresses workshop on 'Roadmap to Strengthen Public Health Preparedness and Response Capabilities of Points of Entry (PoEs) in India'

India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency


Thirty five generic manufacturers sign agreements with MPP for Paxlovid
News | March 18, 2022

Thirty five generic manufacturers sign agreements with MPP for Paxlovid

The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris


Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
Drug Approval | January 21, 2022

Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir

The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list


Natco Pharma signs agreement with Medicines Patent Pool
News | January 20, 2022

Natco Pharma signs agreement with Medicines Patent Pool

This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name